3D Printed Drugs: Triastek closes $20.4 Million Financing

Triastek, a pioneer in the development of 3D printing technologies for the pharmaceutical industry, announced the closing of a $20.4 million Pre-C financing round. Backed by prominent investors such as Guoxin Investment and Goldmine, Triastek continues its journey to provide innovative solutions in drug development and manufacturing.

The financing round was led by Guoxin Investment, with participation from Goldmine Multi-family Office and existing investor Xiaodong Zheng, president of Shanghai Tofflon Science and Technology Co. Ltd. China Renaissance acted as exclusive financial advisor. Triastek has previously attracted prominent investors such as Tasly Holding Group and Matrix Partners China.

Triastek’s proprietary Melt Extrusion Deposition (MED) 3D printing technology, combined with digital formulation development methods, enables complex drug delivery and programmed release. The company is also currently developing new technology processes such as semi-solid extrusion and micro-droplet jetting. These technologies provide broad solutions for pharmaceutical needs, including oral peptides and highly potent products.

Triastek works intensively with global pharmaceutical companies to develop innovative products and advanced technical solutions. This includes strategic partnerships with companies such as Eli Lilly, Merck KGaA and Siemens. The focus is on developing new products through applications of 3D printing technology to improve patient care.

With this latest funding, Triastek is taking significant steps to advance the applications of 3D printing technology in pharmaceuticals. The company confirms its place as a leader in digital pharmaceutical process technologies and continues to strive to provide innovative pharmaceutical products that lead to improved patient outcomes. These developments mark a significant evolution in drug manufacturing and could significantly shape the landscape of pharmaceutical production.